ClinicalTrials.gg
RecruitingNCT07633730Updated Jun 8, 2026

Efficacy of the Erector Spinae Plane Block for Persistent Back Pain in Patients With Ankylosing Spondylitis

An interventional study of Erector spinae plane block(ESBP) in Ankylosing Spondylitis (AS), Back Pain and ESPB, sponsored by Marmara University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Marmara University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 84 studies in Spondylitis, Ankylosing with a site in Turkey — 19 open to participants now, 21 under way, none of them phase 3. Spondylitis, Ankylosing · Turkey.

Planned enrollment
49th of 49
15 · median 60
Started
2026
with 8 others
No phase
37 of 84
12 open now
Primary completion
2027-05
later than 14 of 20 live
Registered
76th of 84
by date

Among the 84 studies in Spondylitis, Ankylosing with a site in Turkey, this one is the 49th largest by planned enrollment of the 49 interventional ones that give a count, is one of 9 that started in 2026, is one of 37 with no phase, reaches primary completion later than 14 of the 20 other live ones, and was the 76th registered.

Spondylitis, Ankylosing

535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

19 of the 84 studies in Spondylitis, Ankylosing with a site in Turkey are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 24 (38%) set no upper age limit and 33 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Spondylitis, Ankylosing with a site in Turkey, or all of them as a file.
02

Study summary

Despite adequate control of disease activity with standard medical therapies, there remains an ongoing need for complementary and interventional approaches for the management of persistent back pain in patients with ankylosing spondylitis. Although the erector spinae plane block has been described in the literature as a safe and effective analgesic intervention for chronic back pain in various patient populations, to the best of our knowledge, no clinical study has specifically evaluated its use for persistent back pain in patients with ankylosing spondylitis receiving medical treatment. Therefore, the present study aims to evaluate the effects of erector spinae plane block on pain severity and clinical outcomes in patients with ankylosing spondylitis whose disease activity is controlled under treatment but who continue to experience persistent back pain.

Read the detailed description

Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease primarily affecting the axial skeleton, including the spine and sacroiliac joints. The most prominent clinical manifestations of AS are chronic back pain and progressive spinal stiffness; however, the disease may also involve peripheral joints and entheses.

The primary goals in the management of AS are to reduce pain and stiffness, preserve functional capacity, and decrease overall disease burden. Nonsteroidal anti-inflammatory drugs (NSAIDs) constitute the first-line treatment, while biologic agents and disease-modifying antirheumatic drugs (DMARDs) are used in appropriate patients.

Back pain in AS represents one of the hallmark symptoms of the disease and mainly arises from inflammation involving the spine and sacroiliac joints. This symptom is frequently associated with functional impairment and reduced quality of life.

Although contemporary treatment strategies can effectively suppress disease activity in many patients, a subset of individuals continue to experience persistent symptoms and disease burden despite treatment, a condition commonly referred to as "residual disease." Residual symptoms are frequently reported even in patients achieving clinical remission or low disease activity, and a considerable proportion of these patients continue to suffer from ongoing pain. Therefore, persistent back pain despite controlled disease activity has emerged as an important unmet clinical need, potentially associated not only with inflammatory mechanisms but also with accompanying mechanical factors and comorbid conditions.

The erector spinae plane (ESP) block is a regional analgesic technique performed under ultrasound guidance by advancing the needle tip into the fascial plane deep to the erector spinae muscle at the level of the transverse process, followed by injection of local anesthetic and steroid agents. Owing to the cranio-caudal spread of the injectate, the ESP block can provide analgesia across multiple dermatomes. In patients with persistent back pain, ESP block has been described as a complementary interventional option administered at thoracic or lumbar levels, either as a single or repeated procedure depending on the clinical scenario, with the aims of reducing pain severity, improving functional status, and decreasing analgesic requirements. However, the current evidence remains limited for many chronic pain indications, consisting predominantly of case reports, case series, and a limited number of clinical studies.

The present study aims to evaluate the effects of erector spinae plane block on pain severity and clinical outcomes in patients with ankylosing spondylitis whose disease activity is adequately controlled under medical treatment but who continue to experience persistent back pain.

03

Conditions studied

  • Ankylosing Spondylitis (AS)
  • Back Pain
  • ESPB
  • Regional Anesthesia

Keywords

  • ESPB
  • Erector Spinae Plane Block
  • Back Pain
  • Ankylosing Spondylitis
  • Persistent back pain
  • Regional anesthesia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65 years
  • Diagnosis of ankylosing spondylitis according to the Modified New York Criteria
  • Patients receiving ongoing treatment with controlled disease activity but persistent back pain
  • Willingness to participate in the study

Exclusion criteria

Exclusion Criteria:

  • (BMI) greater than 35 kg/m²
  • History of thoracic surgery
  • Intellectual disability or mental retardation
  • Presence of major psychiatric comorbidity
  • Congenital spinal anomaly
  • Pregnancy
  • History of bleeding diathesis
  • Presence of active local and/or systemic infection
  • Known allergy to the medications to be injected
  • Hemodynamic instability
  • Active phase of the disease (elevated acute phase reactants, active arthritis findings, etc.)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Active comparator
    Patients with ankylosing spondylitis and resistant persistent back pain who underwent erector spinae

    Patients with ankylosing spondylitis whose disease activity is adequately controlled under medical treatment but who are referred due to persistent back pain will undergo erector spinae plane block. All assessments, including pain severity, disease activity, general functional status, and spinal mobility, will be performed at baseline (T0), 2 weeks after the procedure (T1), and 2 months after the procedure (T2).

    Procedure: Erector spinae plane block(ESBP)

Interventions

  • ProcedureErector spinae plane block(ESBP)

    The procedure will be performed in the prone position under sterile conditions and ultrasound guidance. Using a 22-gauge needle at the T5-T7 vertebral levels, the fascial plane between the deep fascia of the erector spinae muscle group and the transverse process of the vertebra will be accessed. A combination consisting of 5 cc of 0.5% bupivacaine, 4 cc of 0.9% normal saline, and 1 cc dexamethasone (8 mg/2 mL) will then be injected into the targeted plane. The procedure will be performed by experienced algology specialists with more than 15 years of experience in ultrasound-guided interventional procedures and will be administered in two sessions within one week.

06

What researchers measure

Primary outcomes

  1. Numeric Rating Scale (NRS)

    The Numeric Rating Scale is used to assess and monitor pain severity. On the scale, "0" indicates no pain, whereas "10" represents the worst pain imaginable. Patients are asked to rate their pain intensity on a scale ranging from 0 to 10. Due to its simplicity and ease of understanding, the NRS is widely used in clinical practice and research.

    Time frame: Assessments will be performed at baseline (T0), 2 weeks after the erector spinae plane block procedure (T1), and 2 months after the procedure (T2).

Secondary outcomes

  1. Bath Ankylosing Spondylitis Metrology Index (BASMI)

    BASMI is an index used to objectively assess spinal mobility in ankylosing spondylitis through physical examination measurements, including cervical rotation, tragus-to-wall distance, lateral spinal flexion, modified Schober test, and intermalleolar distance. BASMI scores range from 0 to 10, with higher scores indicating clinically significant restriction of spinal mobility and greater structural involvement.

    Time frame: Assessments will be performed at baseline (T0), 2 weeks after the erector spinae plane block procedure (T1), and 2 months after the procedure (T2).

  2. Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein (ASDAS-CRP)

    ASDAS-CRP is a composite index used to assess disease activity in ankylosing spondylitis (AS) and axial spondyloarthritis by combining patient-reported outcomes with the objective inflammatory marker C-reactive protein (CRP). An ASDAS-CRP score ≥2.1 is considered indicative of active disease.

    Time frame: Assessments will be performed at baseline (T0), 2 weeks after the erector spinae plane block procedure (T1), and 2 months after the procedure (T2).

  3. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

    BASDAI is a patient-reported outcome measure used to assess disease activity in ankylosing spondylitis and axial spondyloarthritis. It consists of six questions evaluating fatigue, spinal pain, peripheral joint pain, enthesitis, and morning stiffness experienced during the previous week. BASDAI scores range from 0 to 10, with scores \<4 indicating low disease activity and scores ≥4 indicating clinically significant active disease. A BASDAI score of ≥4 is widely accepted as an important threshold for treatment decision-making and therapeutic escalation.

    Time frame: Assessments will be performed at baseline (T0), 2 weeks after the erector spinae plane block procedure (T1), and 2 months after the procedure (T2).

  4. Bath Ankylosing Spondylitis Functional Index (BASFI)

    BASFI is a patient-reported outcome measure consisting of 10 questions designed to evaluate functional capacity and activities of daily living in patients with ankylosing spondylitis. BASFI scores range from 0 to 10, with higher scores indicating clinically significant functional limitation and a greater impact of the disease on daily life.

    Time frame: Assessments will be performed at baseline (T0), 2 weeks after the erector spinae plane block procedure (T1), and 2 months after the procedure (T2).

  5. Istanbul Low Back Pain Functional Scale (ILBPFS)

    The Istanbul Low Back Pain Functional Scale was developed to evaluate the functional impact of low back pain on activities of daily living in patients with low back pain. The scale consists of 18 items, with total scores ranging from 0 to 18. Higher scores indicate clinically significant increases in functional limitation. In general, scores of 0-6 indicate mild, 7-12 moderate, and 13-18 severe functional impairment.

    Time frame: Assessments will be performed at baseline (T0), 2 weeks after the erector spinae plane block procedure (T1), and 2 months after the procedure (T2).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2027, 11 months after the start.

Of 62 non-industry interventional studies with no phase under Spondylitis, Ankylosing, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 11 months is close to that.

Counting every sponsor, half of 65 studies reached it within 12 months; a quarter within 7 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2026
First posted
Jun 8, 2026
StartActual
Jun 2, 2026
Primary completionEst.
May 2, 2027
CompletionEst.
Jun 2, 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07633730
Lead sponsor
Marmara University
Responsible party
Sponsor
First posted
Jun 8, 2026
Start date
Jun 2, 2026
Primary completion
May 2, 2027 (estimated)
Completion
Jun 2, 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

Fatma B Akdağ, Research Assistant
Contact
fatma.betul820@gmail.com
+90 537 452 96 60
Savaş Şencan, Associate Professor
Contact
savas-44@hotmail.com
+90 537 066 57 13
Fatma B Akdağ, Research Assistant
principal investigator · Marmara University Faculty of Medicine ,Marmara University, Department of Physical Medicine and Rehabilitation
Savaş Şencan, Associate Professor
study director · Algology Division, Department of Physical Medicine and Rehabilitation, Marmara University Faculty of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion